30May 2017

COINFECTION WITH HEPATITIS B AND HEPATITIS C VIRUS: NEW INSIGHTS OF TREATMENT IN THE ERA OF DIRECT ACTING ANTIVIRALS.

  • Endoscopy Unit, Department of Internal Medicine, University Hospital, Prince Sattam Bin Abdulaziz University, Al Kharj, Saudi Arabia.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Coinfection with hepatitis B (HBV) and C virus (HCV) is a major public health issue globally because coinfected patients may experience more rapid and severe liver disease progression. Subsequently, treatment should be prioritized for these patients.Both the European Association for the Study of the Liver (EASL) and The American Association for the study of Liver Diseases (AASLD) suggested that the criteria for optimum treatment for patients who are coinfected based on the viral dominance after viral interactions should be similar to those patients who have hepatitis B or hepatitis C monoifection. The new drugs for HCV treatment, the direct acting antivirals (DAAs), have brought new pathways in treating HCV alone and should be evaluated in HBV/HCV-coinfectedpatients. Unfortunately,thereisan unpredictable risk of HBV reactivation in patients with dual HBV/HCV infection under the new free-interferon regimens using DAAs. Both the EASL and AASLD up-to-date recommendations suggesting close monitoring HBV coinfection, regardless of the infection stage (chronic, occult, resolved), of the HCV genotype or the class of DAAs used.In HBV dominance, nucleos(t)ide analogue (NA) with high antiviral activity (potency) and high genetic barrier should always be considered.Both HBV and HCV treatment could be implemented in synchronously active HBC/HCV coinfectionor HBV reactivation during HCV treatment.

  1. Sagnelli E, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert OpinPharmacother. 2014;15:1337-49.
  2. Mekky Ma, Nasr AM, Saleh MA, Wasif NK, Khalaf M, Aboalamc H, Haredy M. Virologic and histologic characterisation of dual hepatitis B and C co-infection in Egyptian patients. Arab J Gastroenterol. 2013;14:143?147.
  3. Chakravarti A, Verma V, Jain M, Kar P. Characteristics of dual infection of hepatitis B and C viruses among patients with chronic liver disease: a study from tertiary care hospital. Trop Gastroenterol. 2005;26:183?187.
  4. Senturk H, Tahan V, Canbakan B, Dane F, Ulger Y, Ozaras R, Tabak F, Mert A, Ozbay G. Clinicopathologic features of dual chronic hepatitis B and C infection: a comparison with single hepatitis B, C and delta infections. Ann Hepatol. 2008;7:52?58.
  5. Di Marco V, Lo Iacono O, Camma C, Vaccaro A, Giunta M, Martorana G, Fuschi P, Almasio PL, Crax? A. The long term course of chronic hepatitis B. Hepatology. 1999;30:257?264.
  6. Fattovich G, Tagger A, Brollo L, Giustina G, Pontisso P, Realdi G; Alberti A; Ruol A. Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis. 1991;163:400?402.
  7. Crespo J, Lozano JL, de la Cruz F, Rodrigo L, Rodrigueze M, San Miguel G, Artinano E, Pons-Romeroal F. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol. 1994;89:1147?1151.
  8. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998;75:347?354.
  9. Ohkawa K, Hayashi N, Yuki N, Hagiwara H, Kato M, Yamamoto K, Eguchi H, Fusamoto H, Masuzawa M, Kamada T. Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients. J Hepatol. 1994;21:509?514.
  10. Dai CY, Yu ML, Chuang WL, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J GastroenterolHepatol. 2001;16:636?640.
  11. Semnani S, Roshandel G, Abdolahi N, Keshtkar AA, Joshaghani H, Moradi A, Kalavt K, Jabbari A, Kabir MJ, Hosseini SA, Sedaqat SM, Dansesh A, Roshande D. Hepatitis B/C virus co-infection in Iran: a seroepidemiological study. Turk J Gastroenterol. 2007;18:20?21.
  12. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology. 2004;126:1024?1029.
  13. Sagnelli E, Coppola N, Pisaturo M, AddolorataMasiello A, Tonziello G, Sagnelli C, Messina V, Filippini P. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology. 2009;49:1090?1097.
  14. Alberti A, Pontisso P, Chemello L, Fattovich G, Benvegn? L,? Belussi F,? De Mitri MS. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol. 1995;22:38?41.
  15. Raimondo G, Saitta C. Treatment of the hepatitis B virus and hepatitis C virus co-infection: still a challenge for the hepatologist. J Hepatol. 2008;49:677?679.
  16. Bellecave P, Gouttenoire J, Gajer M, Brass V, Koutsoudakis G, Blum HE, Bartenschlager R, Nassal M, Moradpour D. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology. 2009;50:46?55.
  17. Sato S, Fujiyama S, Tanaka M, Yamasaki K, Kuramoto I, Kawano S, Sato T, Mizuno K, Nonaka S. Coinfection of Hepatitis C virus in patients with chronic Hepatitis B infection. J Hepatol. 1994;21:159-166.
  18. Lee LP, Dai CY, Chuang WL, Chang WY, Hou NJ, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chen TJ. Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C coinfected patients. J GastroenterolHepatol. 2007;22:515?517.
  19. Zarski J-P, Bohn B, Bastie A, Jean-Michel Pawlotsky JM, Baud M, Bost-Bezeaux F, van Nhieu JT, Seigneurin JM, Buffet C, Dhumeaux D. Characteristics of patients with dual infection by Hepatitis B and C viruses. J Hepatol. 1998;28:27-33.
  20. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998;75:347?354.
  21. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer. 2005;92:607?612.
  22. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, H?rter D, Nawrocki M, Kruska L, Hensel F, Petry W, H?ussinger D. Prognosis of chronic Hepatitis C: results of a large prospective cohort study. Hepatology. 1998;28:1687-1695.
  23. Pol S, Lucier S, Fontaine H, Dorival C, Petrov-Sanchez V, Bourli?re M, Capeau J, Carrieri P, Larrey D, Larsen C, Marcellin P, Pawlotsky JM, Trinchet JC, Zoulim F, Cacoub P, De Ledinghen V, Dubuisson J, Mathurin P, Negro F, Pageaux GP, Yazdanpanah Y, Wittkop L, Zarski JP, Carrat F. Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: data from the French cohort ANRS CO22 HEPATHER. J Hepatol. 2015;62(Suppl 2):S488?S489. Abstract P0468.
  24. EASL Recommendations on Treatment of Hepatitis C 2016.European Association for the Study of the Liver. J Hepatol. 2017;66:153-194.
  25. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932-54.
  26. Crockett SD, Keeffe EB. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann ClinMicrobiolAntimicrob. 2005;4:13.
  27. Kruse R, Kramer JR, Duan Z, Chen L, El-Serag H, Kanwalet F. Impact of Active Hepatitis B Virus DNA Replication on Clinical Outcomes in Patients With Hepatitis C and B Co-Infection. Gastroenterology. 2014:146( 5suppl):S-925. Abstract 704.
  28. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(5 Suppl):S45-55.
  29. Ganem D and Prince AM. Hepatitis B Virus Infection ? Natural History and Clinical Consequences. N Engl J Med 2004;350:1118-1129.
  30. Wang LS, D\'Souza LS, Jacobson IM. Hepatitis C- A clinical review. J Med Virol. 2016;88:1844-55.
  31. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Apr 18. pii: S0168-8278(17)30185-X. doi: 10.1016/j.jhep.2017.03.021.
  32. Liaw YF. Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. J Gastroenterol. 2002;37(Suppl 13):65?68.
  33. Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, Squadrito G, Tono N. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2006;43:100-107.
  34. Hamzaoui L, El Bouchtili S, Siai K, Mahmoudi M, Azzouz MM. Hepatitis B virus and hepatitis C virus co-infection: A therapeutic challenge. Clin Res HepatolGastroenterol. 2013;37:e16?e20.
  35. Villa E, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, Cremonini C, Bertani H and Manenti F. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol. 2001;96:2973-2977.
  36. Fukuda R, Ishimura N, Hamamoto S, Moritani M, Uchida Y, Ishihara S, Akagi S, Watanabe M, Kinoshita Y. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol. 2001;63:220?227.
  37. De Maria N, Colantoni A, Friedlander L, Leandro G, Idilman R, Harig J and Van Thiel DH. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol. 2000;95:3529?3536.
  38. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology. 2003;37:568?576.
  39. Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, Spengler U, Gruengreiff K, Kaeser T, Schuchmann M, Bergk A, Forestier N, Deterding K, Manns MP, Trautwein C for the Hep-Net B/C Co-infection Study Group. The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol. 2008;49:688?694.
  40. Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu∥ SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su∥ WW, Lin CL?, Jeng YM, Chen PJ, Chen DS. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009;136:496?504.
  41. Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung ST, Yang SS, Kao JH, WW, Lin CL, Yang HC, Chen PJ, Chen DS, Liu CJ. Taiwan Liver-Net Consortium. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology. 2013;57:2135?2142.
  42. Chen LW, Chien RN, Yen CL, Chang JJ, Liu CJ, Lin CL. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection. J GastroenterolHepatol. 2010;25:259?263.
  43. Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, Anania FA, Farley MM. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis. 2015;61:1304-6.
  44. Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T, Brinker A. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med. 2017 Apr 25. doi: 10.7326/M17-0377.
  45. Sulkowski MS, Chuang W-L, Kao J-H, Yang JC, Gao B, Brainard DM, et al. No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection. Clin Infect Dis 2016;63:1202?1204.
  46. Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting? antiviral? ? ClinGastroenterolHepatol 2017;15:132?136.
  47. Takayama H, Sato T, Ikeda F, and Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res. 2016;5:489-491.
  48. De Monte A, Courjon J, Anty R, Cua E2, Naqvi A, Mondain V, Cottalorda J, Ollier L, Giordanengo V. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. J ClinVirol. 2016;78:27-30.
  49. Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, Anania FA, Farley MM. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis. 2015;61:1304-6.
  50. Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J. Med. Case Reports. 2015;9:164
  51. Kimura H, Ohkawa K, Sakakibara M, Imanaka K, Matsunaga T, Miyazaki M, et al. Sustained hepatitis C virus RNA clearance accompanied by elevation of hepatitis B virus DNA after short-term peginterferon-a, ribavirin and simeprevir therapy in a chronic hepatitis patient having dual infection with hepatitis B and C viruses. Kanzo 2015;56:422?427.
  52. Brunetto MR, Cerenzia MT, Oliveri F, Piantino P, Randone A, Calvo PL, Manzini P, Rocca G, Galli G, Bonino F. Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc. J Hepatol 1993;19:431?6.
  53. Liu JY, Sheng YJ, Hu HD, et al. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Virol J 2012; 9:186.
  54. Yalcin K, Degertekin H, Yildiz F, Kilinc N. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with Α-interferon and ribavirin. J Gastroenterol 2003;38:796?800.
  55. US National Institutes of Health. ClinicalTrials.gov 2015. https://clinicaltrials.gov/ct2/show/NCT02555943 First received September 20, 2015.
  56. Cheng HR, Liu CJ, Tseng TC, Su TH, Yang HI, Chen CJ, Kao JH. Host genetic factors affecting spontaneous HBsAgsero-clearance in chronic hepatitis B patients. PLoS One. 2013;8:e53008.
  57. Marrone A, Zampino R, D?Onofrio M, Ricciotti R, Ruggiero G, Utili R. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. J Hepatol. 2004;41:1064?1065.
  58. Coppola N, Stanzione M, Messina V, Pisaturo M, De Pascalis S, Macera M, Tonziello G, Fiore M, Sagnelli C, Pasquale G, Sagnelli E.. Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection. J Viral Hepat. 2012;19:890?896.
  59. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed M, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol. Int. 2012; 6:531?61.

[Georgios Zacharakisand Jamaan M. Al-Zahrani. (2017); COINFECTION WITH HEPATITIS B AND HEPATITIS C VIRUS: NEW INSIGHTS OF TREATMENT IN THE ERA OF DIRECT ACTING ANTIVIRALS. Int. J. of Adv. Res. 5 (May). 1928-1937] (ISSN 2320-5407). www.journalijar.com

Georgios Zacharakis

DOI:

Article DOI: 10.21474/IJAR01/4331      
DOI URL: https://dx.doi.org/10.21474/IJAR01/4331

Download Full Paper

Download PDF No. of Downloads: 27 | No. of Views: 115